Skip to main content
Premium Trial:

Request an Annual Quote

Center for Molecular Medicine to Provide Genotyping Services for COG Leukemia Study

NEW YORK (GenomeWeb News) - The Center for Molecular Medicine will provide genotyping and analysis services to the Children’s Oncology Group to support a study of genetic abnormalities and their association with response to therapies for treatment of childhood leukemia, CMM said today.
 
CMM, based in Grand Rapids, Mich., said that in the first phase of the study it will analyze up to 2,200 matched samples of DNA from pediatric leukemia patients’ blood samples and their leukemic blasts. The aim is to identify and catalog genetic variations that COG can use in its efforts to develop improved diagnostics and therapeutics for childhood leukemia.
 
CMM will “identify and catalog about a million key SNPs” in these samples, said CMM executive director Daniel Farkas.
 
CMM said it will begin testing samples this month, and that Phase I may be completed by spring.
 
COG and CMM are also “working together to identify sources of funding to expand the study to six to eight thousand more specimens,” CMM said in a statement.
 
Financial terms of the agreement were not released.
 
CMM is a clinical diagnostics laboratory formed last year as a joint venture between Spectrum Health and Van Andel Institute.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.